All In Biotech

NDA 065214 · B Braun

Cefoxitin and Dextrose In Duplex Container

Cefoxitin Sodium · Injection

Last checked: Nov 20, 2026Latest source record: Jul 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Mar 10, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

28

7 Phase 3, 2 recruiting

FAERS reports

204

177 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2019.

Cefoxitin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria ( 1 ): Lower respiratory tract infections ( 1.1 ); Urinary tract infections ( 1.2 ); Intra-abdominal infections ( 1.3 ); Gynecological infections ( 1.4 ); Septicemia ( 1.5 ); Bone and joint infections ( 1.6 ); Skin and skin structure infections ( 1.7 ); Prophylaxis ( 1.8 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection and Dextrose Injection and other antibacterial drugs, Cefoxitin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.9 ). 1.1 Lower Respiratory Tract Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae , and Bacteroides species. 1.2 Urinary Tract Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). 1.3 Intra-abdominal Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by...

Mechanism: Cefoxitin is an antibacterial drug [ see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 10, 2006 Original approval
2 products under this application
  • CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER · CEFOXITIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER · CEFOXITIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefoxitin" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use19
  • rash13
  • drug hypersensitivity12
  • anaphylactic shock11
  • nausea11
  • pneumonia11
  • thrombocytopenia11
  • diarrhoea10
  • acute kidney injury9
  • leukopenia9
  • platelet count decreased9
  • pyrexia9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20071
20082
20091
20101
20111
20125
20133
20145
20156
201618
201715
201822
201922
20208
202112
202211
202322
202428
20258
202610

Recalls

1 FDA enforcement reports for this application.

  • Nov 21, 2013 · Class I · Terminated

    Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 418 on PubMed

Sponsor: B Braun

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.